Biotechs Pull Offerings Totaling $155M Amid Weak Markets
Two biotechs nixed stock offerings totaling $155 million on Monday, including an estimated $86 million initial public offering by rare-disease treatment developer Apellis Pharmaceuticals Inc., providing fresh evidence that issuers are...To view the full article, register now.
Already a subscriber? Click here to view full article